Welcome to our dedicated page for Tenax Therapeutics SEC filings (Ticker: TENX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Tenax Therapeutics, Inc. (TENX) provides access to the company’s official disclosures as a Nasdaq-listed, Phase 3, development-stage pharmaceutical company. Through these filings, Tenax reports material events, clinical and corporate milestones, and periodic financial results related to its cardiopulmonary drug development programs.
Recent Form 8-K filings have documented key developments in the company’s PH-HFpEF program. These include announcements that the European Patent Office issued an Intention to Grant a patent covering TNX‑103 (oral levosimendan), other levosimendan formulations, and its active metabolites for use in PH-HFpEF, and that Tenax completed a prespecified blinded sample size re-estimation in the registrational Phase 3 LEVEL trial of TNX‑103 in the United States and Canada. Other 8‑K filings describe the initiation of the global Phase 3 LEVEL‑2 study and amendments to the company’s license agreement with Orion Corporation, expanding Tenax’s rights to develop, commercialize, and manufacture orally administered levosimendan products.
Filings also include earnings-related 8-Ks, where Tenax furnishes press releases detailing quarterly financial results and corporate updates. These disclosures discuss research and development spending on the LEVEL and LEVEL‑2 trials, general and administrative expenses, and the company’s cash position and funding outlook, all within the framework of SEC reporting requirements.
On this page, users can review Tenax’s SEC submissions, including current reports and other documents that may be filed over time. Stock Titan enhances this information with AI-powered summaries that explain the significance of complex filings, highlight clinical and IP milestones, and help readers quickly identify items related to Phase 3 trial progress, licensing arrangements, and the company’s PH-HFpEF strategy. This resource supports investors and researchers seeking a structured view of TENX’s regulatory and financial reporting history.
Tenax Therapeutics CEO Christopher Thomas Giordano has filed a Schedule 13D reporting a 6.79% beneficial ownership stake in the company’s common stock. He is deemed to beneficially own 1,252,965 shares, based on 17,197,613 shares outstanding as of March 6, 2026.
The position consists of 2,605 shares of common stock and 1,250,360 shares underlying stock options with various exercise prices. Giordano states he holds the shares for investment purposes and may buy or sell additional shares over time, but has no current plans to change control or the company’s corporate structure.
Tenax Therapeutics, Inc. files its annual report as a Phase 3, development-stage pharma company focused on cardiopulmonary diseases, led by oral levosimendan (TNX-103) for pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF).
The company is running two global Phase 3 trials, LEVEL and LEVEL-2, targeting 6‑minute walk distance and quality-of-life endpoints, with open-label extensions to build the long-term safety database regulators requested. Imatinib (TNX-201) for pulmonary arterial hypertension is retained but deprioritized.
Tenax strengthened its balance sheet with a $25.0 million private placement in March 2025 and about $100.0 million raised in August 2024, reporting $97.6 million in cash and cash equivalents as of December 31, 2025. The business model depends on successful Phase 3 outcomes, regulatory approvals, and future commercialization or partnerships under an exclusive levosimendan license from Orion.
Tenax Therapeutics reported 2025 results and highlighted major progress in its Phase 3 program for levosimendan (TNX-103) in pulmonary hypertension with preserved ejection fraction (PH-HFpEF). The company reached its randomization target of 230 patients in the Phase 3 LEVEL trial and expects topline data in the third quarter of 2026. A second global registrational Phase 3 study, LEVEL-2, began in December 2025, with enrollment anticipated to complete by the end of 2027, and an open-label extension will allow continued TNX-103 access.
Cash and cash equivalents were $97.6 million as of December 31, 2025, and Tenax expects this to fund operations through 2027. R&D expenses rose to $10.5 million for the fourth quarter and $32.7 million for the full year 2025, compared with $4.6 million and $12.7 million in 2024, mainly due to advancing LEVEL and initiating LEVEL-2. G&A expenses increased to $5.9 million for the quarter and $23.7 million for the year, versus $2.7 million and $6.8 million in 2024, largely from higher stock-based compensation and professional fees. Net loss widened to $15.5 million for the quarter and $52.6 million for 2025, compared with $6.3 million and $17.6 million in 2024.
Tenax Therapeutics, Inc. reporting persons led by Logos Global Management disclose beneficial ownership of 615,000 shares of Common Stock, representing 9.9% of the class. The percentage is calculated using 6,243,575 shares outstanding as of
Tenax Therapeutics, Inc. received an updated Schedule 13G/A filing from Venrock-affiliated investment entities reporting their beneficial ownership in the company. The group, including Venrock Healthcare Capital Partners III, L.P. and related funds and individuals, reports beneficial ownership of 692,959 shares of common stock as of December 31, 2025.
This position represents 9.99% of Tenax’s common stock, based on 6,243,575 shares outstanding as of November 11, 2025 plus shares issuable upon warrant exercise. The holdings are primarily through pre-funded warrants and common warrants that are subject to a “Beneficial Ownership Blocker” preventing ownership above 9.99%.
Biotechnology Value Fund and related entities, including BVF Partners and Mark N. Lampert, report beneficial ownership of 768,200 shares of Tenax Therapeutics common stock, representing approximately 9.99% of the outstanding shares as of December 31, 2025.
The group holds a mix of common shares and pre-funded warrants, with only 428,651 of 10,099,974 underlying pre-funded warrant shares currently counted due to a 9.99% ownership blocker. They also hold 5,209,174 additional warrants that are immediately exercisable in principle but not currently exercisable because of similar 9.99% ownership limits.
The filing clarifies how various BVF funds, their general partners, BVF Inc. and Mr. Lampert may be deemed to share voting and dispositive power, while several entities formally disclaim beneficial ownership of securities held by affiliated funds or accounts. The group certifies the holdings are not for the purpose of changing or influencing control of Tenax.
Tenax Therapeutics, Inc. received an amended ownership report showing that Point72 Asset Management, Point72 Capital Advisors and Steven A. Cohen beneficially own 423,415 shares of Tenax common stock, representing 6.8% of the outstanding class as of December 31, 2025.
The shares are held by Point72 Associates, LLC, an investment fund managed by Point72 Asset Management, which has investment and voting power under an investment management agreement. Point72 Capital Advisors is the general partner of Point72 Asset Management, and Mr. Cohen controls both entities.
The reporting persons certify that the Tenax shares were not acquired and are not held to change or influence control of the company, but instead are reported on a passive basis under the beneficial ownership rules.
Lind Global Fund II LP and related reporting persons disclose a passive stake in Tenax Therapeutics, Inc. They report beneficial ownership of 442,480 warrants to purchase common stock, representing 6.62% of Tenax’s common stock. The warrants are subject to a 9.9% beneficial ownership cap on exercise.
Lind Global Partners II LLC, as general partner of Lind Global Fund II LP, and Jeff Easton, as managing member of Lind Global Partners II LLC, may each be deemed to have sole voting and dispositive power over these securities. The reporting persons certify the holdings are not for the purpose of changing or influencing control of Tenax.
Tenax Therapeutics, Inc. received an updated ownership report from Perceptive Advisors and related parties. Perceptive Life Sciences Master Fund, Ltd. directly holds 569,308 shares of Tenax common stock. Based on 6,243,575 shares outstanding as of November 11, 2025, the filing reports beneficial ownership of 9.1% of the company.
Perceptive Advisors, as investment manager to the Master Fund, and its managing member Joseph Edelman may each be deemed to beneficially own the same 569,308 shares, with shared voting and shared dispositive power and no sole power. The reporting persons certify that the shares were not acquired to change or influence control of Tenax.
Tenax Therapeutics, Inc. received an amended Schedule 13G/A (Amendment No. 3) showing a significant institutional position. Dellora Investments LP, as investment adviser to its funds, reports beneficial ownership of 401,071 shares of Tenax common stock, or 6.4% of the class, while Dellora Investments Master Fund LP directly holds 355,257 shares, or 5.7%. These percentages are based on 6,243,575 shares outstanding as of November 11, 2025, as stated in Tenax’s Form 10-Q. Voting and dispositive power over these shares is shared, with no sole power reported. Dellora Investments LP and its principal, Kevin Pyun, state that the holdings are in the ordinary course of business and certify they are not held to change or influence control of Tenax. They also expressly disclaim beneficial ownership beyond what may be deemed under securities laws.